Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill

 
• By Derrick Gingery

Legislation in development also could create an option for tentative approval of interchangeable biosimilars.

shared biosimilar exclusivity
Sponsors may be confused by the statutory language governing first interchangeable exclusivity and whether multiple first filers could share it. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock image

Interchangeable biosimilar sponsors may gain the ability to share the associated exclusivity, similar to what often occurs among small-molecule generics.

A bill in development would ensure all sponsors who are the “first filers” for interchangeable status can receive the one year of exclusivity, as well as allow tentative approval of subsequent

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products